Sign up for the latest Biomark news
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
Menu
Menu
Press and News Releases
The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics Inc.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
News
Press Release – BIOMARK ANNOUNCES CLOSING OF $1,5 MILLION FINANCING ROUND TO ACCELERATE COMMERCIALIZATION OF ITS LIQUID BIOPSY TECHNOLOGY
BIOMARK ANNOUNCES CLOSING OF $1,5 MILLION FINANCING ROUND TO ACCELERATE COMMERCIALIZATION OF ITS LIQUID BIOPSY
May 4, 2022
News
CSE Form 7 – Monthly Progress Report – BioMark Diagnostics Inc. – Mar 2022
FORM 7MONTHLY PROGRESS REPORT Name of Listed Issuer: BioMark Diagnostics Inc. _____ (the
May 4, 2022
News
BIOMARK TO PRESENT new CANCER SCREENING DATA using the LDTD-MS/MS technique AT THE ANNUAL ASMS Conference on Mass Spectrometry
BIOMARK TO PRESENT NEW CANCER SCREENING DATA USING THE LDTD-MS/MS TECHNIQUE AT THE ANNUAL ASMS
April 29, 2022
News
BioMark Monthly Progress Report April 4 2022
FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed
April 7, 2022
News
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patient Receiving Immunotherapy
Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
June 29, 2021
News
BIOMARK RECEIVES $825K GRANT TO DEVELOP ITS LIQUID BIOPSY ASSAY FOR LUNG CANCER SCREENING
Vancouver, British Columbia – (June 1st, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
June 1, 2021
News
BIOMARK REÇOIT UNE SUBVENTION DE 825 K $ POUR DÉVELOPPER SON TEST DE BIOPSIE LIQUIDE POUR LE DÉPISTAGE DU CANCER DU POUMON
Vancouver, Colombie-Britannique – (1er juin 2021) – BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B)
June 1, 2021
News
BIOMARK ANNOUNCES CHANGE OF AUDITOR
Vancouver, British Columbia – (May 31, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
May 31, 2021
Full Archives
Investor Inquires
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]
Pages
Menu
Latest Posts
Menu
Site Policies
Menu